This short article describes how Organovo is using a novel technology called bioprinting to produce liver and kidney tissues that could help reshape the way drugs are tested and organs are transplanted in our days. It also discusses the challenges and potential effects on society.
BenevolentAI is a UK-based biotechnology company betting on machine learning and artificial intelligence as their competitive advantage at all stages of the drug development process. Will this bet pay off or will BenevolentAI fail to create meaningful innovation in the biotech space?
3D printing technology has made significant advancements in the past few years. Can 3D printing be used in orthopaedics? Is this technology ready for surgery? How could orthopaedic practices best position themselves?
How close is Organovo to bio-printing implantable human liver tissue? Will it be able to afford the time required to achieve this monumental step in healthcare?
Imagine preventing the onset of diabetes, Alzheimer's, or cancer through eating the right foods. Rather than wondering if kale eaten today will truly lead to longevity tomorrow, envision a grocery store shelf that told you exactly which ingredients to eat depending on your specific health needs. Food technology start-up Nuritas is hoping to make that scenario a reality. By harnessing solutions that nature has already given us, Nuritas is using machine learning to identify the exact food-derived bioactive peptides that can cure or prevent a particular disease.
Machine learning has been touted as a potential cure-all for high drug prices. A number of leading biopharmaceutical companies like Roche have made some large bets in using artificial intelligence tools to improve drug development, but it remains to be seen if machine learning is living up to its hype.
Prellis Biologics' holographic 3D printing of biomaterial and ethical considerations surrounding manufactured organs.
General Electric is using 3D printing to lead cutting-edge innovation in the healthcare space and will ultimately bring better, customized medical technologies to market faster and more cost-effectively.
Assessment of Berg's (Boston based biotech) strategy in the short and medium term with respect to its AI, Interrogative Biology and drug development.
Put down that pipette! Transcriptic is turning the costs structure of biotechnology on its head and making experimental results more reliable by using standardized, coded protocols and automated lab equipment.